Unknown OBSERVATIONAL NCT06134635

Short-term Effect of PCSK9 Inhibitor in Patients With Acute Ischemic Stroke

Short-term Effect of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor in Chinese Population With Acute Ischemic Stroke: the Singe-center Real-world Study

Sponsor: Xuanwu Hospital, Beijing

Conditions Acute Ischemic Stroke

Interventions Evolocumab Statins

Updated 4 times since 2023 Last updated: Nov 14, 2023 Started: Dec 1, 2023 Primary completion: Nov 1, 2024 Completion: Dec 1, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A observational or N/A phase clinical study on Acute Ischemic Stroke, this trial is ongoing. The trial is conducted by Xuanwu Hospital, Beijing and has accumulated 4 data snapshots since 2023. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

4 versions recorded

Dec 2025 — Present [monthly]

Unknown

Status: Not Yet Recruiting → Unknown
Sep 2024 — Dec 2025 [monthly]

Not Yet Recruiting
Jul 2024 — Sep 2024 [monthly]

Not Yet Recruiting
Dec 2023 — Jul 2024 [monthly]

Not Yet Recruiting

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Xuanwu Hospital, Beijing

Data source: Xuanwu Hospital, Beijing

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.